Loading…
Based on limited metadata, Inopak Ltd, a drug manufacturer, received an FDA Warning Letter on February 21, 2019, indicating compliance issues with federal drug regulations. While the specific violations cannot be detailed without access to the full letter text, the warning falls under FDA's drug product oversight authority. The company was directed to address deficiencies in their manufacturing, quality control, or regulatory compliance procedures to meet current Good Manufacturing Practice (CGMP) standards or other applicable drug regulations.